Avidity Partners 13F holdings, Q4 2021
Holdings as of December 31, 2021 · filings on SEC EDGAR · latest filing →
Avidity Partners disclosed 97 US equity positions worth $4.7bn in its Q4 2021 13F filing. The largest position was ABBV at 5.7% of the reported book, followed by ZNTL and ARVN. Against the Q3 2021 filing, it opened 5 new positions, added to 34 and reduced 7 among the top 50 holdings.
What did Avidity Partners own in Q4 2021? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q3 2021 |
|---|---|---|---|---|---|---|---|
| 1 | ABBV ABBVIE INC | Healthcare | 5.7% | $268.8m | 1,985,000 | 23% | added |
| 2 | ZNTL ZENTALIS PHARMACEUTICALS INC | Healthcare | 4.8% | $228.2m | 2,715,000 | 9% | added |
| 3 | ARVN ARVINAS INC | Healthcare | 4.4% | $207.6m | 2,527,973 | 13% | added |
| 4 | AVTR AVANTOR INC | Healthcare | 4.3% | $201.9m | 4,792,000 | 48% | added |
| 5 | AZN ASTRAZENECA PLC | Healthcare | 3.5% | $167.0m | 2,867,200 | 103% | added |
| 6 | BIOHAVEN PHARMACTL HLDG CO L | 3.3% | $157.1m | 1,140,000 | 22% | added | |
| 7 | BAX BAXTER INTL INC | Healthcare | 3.2% | $151.5m | 1,765,000 | 105% | added |
| 8 | ELV ANTHEM INC | Healthcare | 3.2% | $148.8m | 321,000 | – | new |
| 9 | PFE PFIZER INC | Healthcare | 2.6% | $123.4m | 2,090,000 | 104% | added |
| 10 | MIRATI THERAPEUTICS INC | 2.5% | $118.3m | 806,400 | -24% | reduced | |
| 11 | IVERIC BIO INC | 2.5% | $116.3m | 6,955,000 | 70% | added | |
| 12 | UTHR UNITED THERAPEUTICS CORP DEL | Healthcare | 2.5% | $115.6m | 535,000 | 52% | added |
| 13 | ARENA PHARMACEUTICALS INC | 2.4% | $113.0m | 1,215,500 | 7% | added | |
| 14 | HORIZON THERAPEUTICS PUB L | 2.3% | $109.1m | 1,012,000 | 23% | added | |
| 15 | NBIX NEUROCRINE BIOSCIENCES INC | Healthcare | 2.3% | $107.3m | 1,260,000 | 48% | added |
| 16 | 2655787D BLUEPRINT MEDICINES CORP | 2.3% | $106.6m | 995,000 | 20% | added | |
| 17 | SEAGEN INC | 2.2% | $105.9m | 685,000 | 28% | added | |
| 18 | SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 2.2% | $105.6m | 4,823,400 | 0% | held |
| 19 | LLY LILLY ELI & CO | Healthcare | 2.0% | $95.2m | 344,800 | 4% | added |
| 20 | CATALENT INC | 1.9% | $89.0m | 695,000 | 75% | added | |
| 21 | NTRA NATERA INC | Healthcare | 1.9% | $87.8m | 940,000 | 47% | added |
| 22 | HO1 HOLOGIC INC | 1.7% | $81.5m | 1,064,000 | 13% | added | |
| 23 | IOVA IOVANCE BIOTHERAPEUTICS INC | Healthcare | 1.5% | $72.2m | 3,780,000 | 159% | added |
| 24 | SHC SOTERA HEALTH CO | Healthcare | 1.5% | $69.7m | 2,960,000 | 24% | added |
| 25 | NUVB NUVATION BIO INC | Healthcare | 1.3% | $62.8m | 7,382,488 | 2% | added |
| 26 | ALNY ALNYLAM PHARMACEUTICALS INC | Healthcare | 1.3% | $62.7m | 370,000 | -13% | reduced |
| 27 | UNH UNITEDHEALTH GROUP INC | Healthcare | 1.3% | $61.8m | 123,100 | – | new |
| 28 | VRTX VERTEX PHARMACEUTICALS INC | Healthcare | 1.3% | $61.5m | 280,000 | -70% | reduced |
| 29 | IDYA IDEAYA BIOSCIENCES INC | Healthcare | 1.3% | $60.4m | 2,553,000 | 5% | added |
| 30 | RARE ULTRAGENYX PHARMACEUTICAL IN | Healthcare | 1.2% | $58.9m | 700,000 | 54% | added |
| 31 | ARWR ARROWHEAD PHARMACEUTICALS IN | Healthcare | 1.2% | $58.0m | 875,000 | 30% | added |
| 32 | STVN STEVANATO GROUP S P A | 1.2% | $57.1m | 2,541,893 | 0% | held | |
| 33 | 2JQ GRITSTONE BIO INC | 1.2% | $56.2m | 4,370,000 | -2% | reduced | |
| 34 | KEZAR LIFE SCIENCES INC | 1.1% | $54.0m | 3,228,200 | 1142% | added | |
| 35 | ACET ADICET BIO INC | Healthcare | 1.1% | $53.1m | 3,034,004 | 25% | added |
| 36 | AVIDITY BIOSCIENCES INC | 0.9% | $43.1m | 1,815,000 | 10% | added | |
| 37 | KYMR KYMERA THERAPEUTICS INC | Healthcare | 0.9% | $42.5m | 670,000 | 30% | added |
| 38 | IMCR IMMUNOCORE HLDGS PLC | Healthcare | 0.9% | $42.1m | 1,230,000 | 12% | added |
| 39 | CRBU CARIBOU BIOSCIENCES INC | Healthcare | 0.9% | $40.4m | 2,674,067 | 8% | added |
| 40 | INSM INSMED INC | Healthcare | 0.8% | $39.5m | 1,450,000 | 12% | added |
| 41 | ORTHO CLINICAL DIAGNOSTICS H | 0.8% | $38.3m | 1,790,000 | -25% | reduced | |
| 42 | PHAT PHATHOM PHARMACEUTICALS INC | 0.8% | $37.3m | 1,896,000 | – | new | |
| 43 | ESSA PHARMA INC | 0.7% | $34.9m | 2,460,000 | 0% | held | |
| 44 | AMN AMN HEALTHCARE SVCS INC | Healthcare | 0.7% | $34.3m | 280,100 | – | new |
| 45 | LEGN LEGEND BIOTECH CORP | Healthcare | 0.7% | $33.2m | 711,900 | -20% | reduced |
| 46 | ATEC ALPHATEC HLDGS INC | Healthcare | 0.7% | $31.7m | 2,773,000 | -0% | held |
| 47 | BELLUS HEALTH INC NEW | 0.6% | $30.4m | 3,775,000 | -24% | reduced | |
| 48 | VIR VIR BIOTECHNOLOGY INC | Healthcare | 0.6% | $29.3m | 700,000 | 36% | added |
| 49 | AXSM AXSOME THERAPEUTICS INC | Healthcare | 0.6% | $29.3m | 775,000 | – | new |
| 50 | SEASPINE HLDGS CORP | 0.6% | $27.4m | 2,010,000 | 3% | added |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.